1 / 32

BRAIN TUMORS

BRAIN TUMORS. Elshami Elamin, MD. Introduction. Intracranial neoplasms arise from: Brain cells Meninges Pituitary gland Skull Residual embyronic tissue Mets from lung, breast etc… Most common solid tumors in children 2 nd cause of cancer death in chlidren. Symptoms, Signs. Headache

rehan
Download Presentation

BRAIN TUMORS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BRAIN TUMORS Elshami Elamin, MD

  2. Introduction • Intracranial neoplasms arise from: • Brain cells • Meninges • Pituitary gland • Skull • Residual embyronic tissue • Mets from lung, breast etc… • Most common solid tumors in children • 2nd cause of cancer death in chlidren

  3. Symptoms, Signs • Headache • N/V • Papilledema • Lateralizing signs; • Hemiparesis • Aphasia • Visual-field deficits • Seizures • Altered Mental Status

  4. Diagnosis • MRI; (gold standard) • To define number of met nodules • Leptomeningeal dz • High G or malignant tumors are enhancing masses in the white matter surrounded by edema • Low G gliomas are nonenhancing • Magnetic Resonance Spectroscopy: • Differentiate between low and high G gliomas • CT scan • PET scan (75% sensitivity, 83% specificity)

  5. PATHOLOGY • Gliomas arise from: • Astrocytes • Oligodendrocytes • Ependymomas: • Low G histologically • High recurrence rate • Medulloblastomas: • High G • Primitive Neuroectodermal Tumors (PNETs): • High G • Pineoblastomas, neuroblastomas • Extra-axial • Meningiomas

  6. GRADING of GLIOMAS • Based on endothelial proliferation, cellular pleomorphism, mitosis, necrosis. • High Grade: • GBM • Anaplastic astrocytoma • Anaplastic oligodendroglioma • Gliosarcoma • Low Grade: • Astrocytoma • Oligodendrogioma • Mixed oligoastrocytoma

  7. STAGING • Not applicable in primary Brain tumors: • Locally invasive • Do not spread to LN or distant organs • Enhanced complete spinal MRI and CSF eval: • Medulloblastoma • Ependymoma • PENT

  8. PROGNOSIS • With conventional treatment: • Anaplastic astrocytoma: MS is 3 Yrs • GBM: MS is 1 Yr • Low G gliomas: MS is 5-10 Yrs • Pts >40Yrs: MS is < 5 Yrs • Brain mets: MS 4-6 m • Single met treated with surgery/G-K: MS > 40Wks

  9. TREATMENT • Supportive: • Anticonvulsant • Seizure at presentation • Prophylaxis only during peri-operative period • Steroids; • Most pts stop steroids when complete RT • If steroids >6 wks: • PCP prophylaxis • Definitive:

  10. Surgery • Goals of surgery: • histologic diagnosis • reducing tumor burden and associated mass effect • maintaining or reestablishing pathways for CSF flow • achieving potential “cure” by gross total removal

  11. RT • Brachytherapy • Radiosurgery • Gamma Knife • iodine-131–labeled antitenascin monoclonal antibody

  12. Adult Low-Grade Infiltrative SupratentorialAstrocytoma/Oligodendroglioma

  13. Management • MRI compatible with primary brain tumor: • Maximal safe resection • Feasible: • post-op MRI • >45Y; Observe or Post-op RT • <45Y; observe • Not feasible: • Stereotactic or open biopsy • Post-op observe, RT, or Chem • F/U: MRI q3-6m x 5Yrs • Recurrence: • Surgery, RT, Chemo

  14. low-grade gliomas • complete surgical resection of hemispheric astrocytomas • Incomplete resection: • Astrocytoma: Post-op RT • oligodendrogliomas or mixed gliomas: may benefit from chemotherapy • Recurrent unresectable dz • RT

  15. Adult Intracranial Ependymoma or Anaplastic Ependymoma • MRI/CT compatible with primary brain tumor: • Maximal resection: (Stereotactic or open biopsy if not feasible) • Postop staging and Adj therapy: • Negative post-op MRI brain,spine +/- CSF • Limited-field RT • Positive post-op MRI brain, spine +/- CSF • Craniospinal RT • F/U: • MRI/CT q3-6mx2Y, then q6-12m • Recurrence: • Resection, RT or Chemotherapy or supportive care

  16. Anaplastic Astrocytoma/AnaplasticOligodendroglioma/ Glioblastoma Multiforme

  17. MRI suggestive of high-G glioma: • Multidisciplinary planning • Maximal Resection • Feasible • Max excision +/- BCNU wafer • Not feasible (Stereotactic or open biopsy)

  18. Adjuvant Therapy • Anaplastic astrocytoma or Anaplastic oligodendroglioma: • Adj RT +/- Chemo • Glioblastoma Multiforme (GBM): • s/p BCNU wafer: • Adj RT ± chemotherapy • No BCNU wafer: • Adj RT ± concurrent and adj temozolomide

  19. High G Gliomas • Post-op RT: • Involved-field 60Gy prolong Survival • 50% of anaplastic astrocytomas respond • 25% of GBM respond • Complete response is rare

  20. High G Gliomas • Adj chemo + RT prolong survival: • BiCNU • PCV • Temozolomide • GBM: Adj Temodar + RT standard of care

  21. Chemotherapeutic regimens for gliomas • Single-agent BiCNU • BiCNU 200 mg/m2 IV q8wk • (maximum cumulative dose,1,500 mg/m2) • Single-agent temozolomide • Temozolomide 150-200 mg/m2 PO on days 1-5 • Repeat cycle every 28 days. • Standard PCV • Procarbazine 60 mg/m2/d PO on days 8-21 • Lomustine (CeeNu) 110 mg/m2 PO on day 1 • Vincristine 1.4 mg/m2 IV on days 8 and 29 • (maximum dose, 2 mg) • Repeat cycle every 6-8 weeks, optimally for 6 cycles. • Intensified PCVa • Procarbazine 75 mg/m2/d PO on days 8-21 • Lomustine (CeeNu) 130 mg/m2 PO on day 1 • Vincristine 1.4 mg/m2 IV on days 8 and 29 • (no dose limit) • Repeat cycle every 6 weeks.

  22. High G Gliomas F/U • MRI 2-6 wk after RT • Then every 2-3 m x 2-3 y

  23. High G Gliomas F/U • MRI 2-6 wk after RT: • Then every 2-3 m x 2-3 y • Recurrence: • Diffuse, Multiple: • Best supportive care if poor PS • chemo • Surgery for symptomatic, large lesions • Local: • Resectable: surgery +/- BCNU polymer, RT, chemo • Unresectable: RT, chemo

  24. Limited (1-3) mets • SCLC or Disseminated systemic dz: • WBRT • Limited systemic disease: • Surgery or Stereotactic radiosurgery • consider WBRT • If unresectable; WBRT and/or radiosurgery

  25. >3 Metastatic Lesions • WBRT ± stereotactic radiosurgeryc

  26. Leptomeningeal disease • DIAGNOSIS: • Positive CSF cytology OR • Positive MRI with supportive clinical OR • CSF findings in a pt known to have cancer OR • Signs and symptomswith supportive CSF in apt known to have amalignancy

  27. Leptomeningeal diseaseTreatment • Poor risk: • Palliative RT, supportive care • Good risk: • IT chemo • Palliative RT to symptomatic/bulky sites • Systemic chemo

  28. Leptomeningeal disease • CSF flow scan: • Normal flow: • Induction IT chemo x 4-6wks • Recheck CSF • Abnormal flow: • RT to site of obstruction +/- IT chemo • Repeat CSF flow scan

  29. Leptomeningeal diseasePost-induction Therapy • Negative CSF: • Maintenance IT chemo • Monthly CSF • Positive CSF: • Clinical leptomeningeal dz; • Supportive care, RT, chemo • No Clinical leptomeningeal dz; • Continue IT chemo • CSF continues to be +ve: • Supportive care

  30. NonimmunosuppressedPrimary CNS Lymphoma • CT/MRI suggestive of lymphoma: • Hold steroids, if possible • CSF, Biopsy • Slit lamp eye exam • HIV test • Spinal MRI

  31. NonimmunosuppressedPrimary CNS LymphomaTREATMENT • Good PS, CrCl > 50: • High-dose MTX-based +/- RT • LP or spinal MRI +ve, • consider IT chemo • Poor PS, CrCl < 50: • Whole-brain RT (45 Gy) or Chemotherapy • Eye exam +ve • RT to orbits • LP or spinal MRI +ve, • consider IT chemo + focal spinal RT

  32. Metastatic Spine Tumors • Asymptomatic: • Surgery or RT or Chemo or Observation • Symptomatic (Pain, Neuro): • Steroids if abnormal neuro exam • Spinal MRI: • Spinal Cord Compression: • Surgery if: • Spinal instability • Radioresistant • Rapid neuro deterioration • Unknown primary • Previous RT • RT • Chemo • No Spinal Cord Compression: • RT, Vertebroplasty, Surgery if spinal instability

More Related